GentiBio
John is the Director of the Process Development team at GentiBio. John has worked in multiple positions and companies across his 20+ years in the industry, including roles in Biologics Manufacturing at GlaxoSmithKline, biologics process development at Janssen (J&J) Pharmaceuticals, and cell therapy process development at Dendron and Juno Therapeutics. His work at Juno developing and refining the Breyanzi CAR-T cell therapy manufacturing process was critical for the successful commercialization of this life-saving product. In his most recent role at Bristol Meyers Squibb, John led a Global Manufacturing Sciences and Technology lab team supporting two commercial CAR-T products. Northeast Philadelphia born and raised, John obtained a BA in Biology from Holy Family University and an MS in Biotechnology from the University of Pennsylvania.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.